Loading the records…
Loading the records…
Leidos Holdings ($LDOS) received a $484M delivery order from NIH for NCI operations, representing ~1.6% of annual revenue. This contract is supported by legislative efforts to strengthen cancer research (S5554) and biotech infrastructure (S5502). The award reinforces Leidos' position in federal healthcare IT and research services.
Leidos' stock may see modest upside from this award as it reinforces its role in federal health IT. The broader healthcare IT sector, including companies like IQVIA ($IQV), could benefit from increased NIH funding. However, the impact is incremental given Leidos' size and the contract's nature as a task order under an existing vehicle.
The Department of Health and Human Services, through the National Institutes of Health, awarded a $484M delivery order to Leidos Biomedical Research Inc. for operational support of the National Cancer Institute (NCI) for fiscal years 2026-2027. This task order covers a range of services including research administration, IT support, and program management for NCI's cancer research initiatives.
Leidos Biomedical Research Inc. is a wholly-owned subsidiary of Leidos Holdings ($LDOS), a publicly traded defense and healthcare IT services company. With annual revenue of $15.3B (FY2025), this $484M contract adds approximately $242M per year, a 1.6% revenue boost. While not transformative, it provides predictable cash flow and demonstrates Leidos' continued partnership with NIH. Leidos' health segment has been a growth driver, and this award solidifies its role in federal biomedical research.
Legislative tailwinds support this contract. S5554, a bill to enhance ovarian cancer awareness and genetic counseling, directly aligns with NCI's mission and could lead to expanded programs and future task orders. S5502, focused on protecting biotechnology infrastructure, signals sustained federal investment in the biotech sector, benefiting companies like Leidos that operate in this space. These bills, while not directly appropriating funds for this specific order, indicate congressional support for cancer research and biotech resilience.
Downstream, subcontractors and suppliers may benefit. Clinical research organizations such as IQVIA ($IQV) and laboratory service providers could see increased demand as NCI operations expand. However, the primary impact is on Leidos itself, as the prime contractor.
Historically, Leidos has consistently won large task orders from NIH, contributing to its stable revenue base in health and civil markets. Similar awards have historically supported Leidos' stock performance due to predictable cash flows and strong government relationships. Investors should view this as a positive but incremental development for Leidos.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Direct award of a delivery order for NCI operational support services.
Who must act
Department of Health and Human Services, National Institutes of Health (NIH) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings.
What happens
$484M added to Leidos' contract backlog over FY2026-FY2027, representing approximately $242M in annual revenue, or ~1.6% of Leidos' FY2025 revenue of $15.3B.
Stock impact
Leidos' health and civil segment, which includes biomedical research services, will see a direct revenue boost. The contract reinforces Leidos' position as a key NIH partner and provides stable, multi-year cash flows. Given Leidos' net margin of 1.3% in FY2025, this contract could contribute modestly to profitability.
Matched on shared policy language across AI analyses, with ticker & timing weight
LEIDOS BIOMEDICAL RESEARCH INC: $484M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $485M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $826M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $338M Department of Health and Human Services Contract
Executive orders & memoranda affecting the same sectors or companies
This proclamation reaffirms U.S. leadership in space exploration, declaring outer space open to development and permanent settlement by American citizens. It sets goals for a return to the Moon by 2028 and a future Mars mission, while emphasizing support for the commercial space industry. The action does not invoke specific legal authorities or direct new funding but signals continued policy focus on space.
The President invokes Section 232 of the Trade Expansion Act to declare that imports of robotics, industrial machinery, and their components threaten national security, and directs the Secretary of Commerce and USTR to negotiate agreements with trading partners to adjust these imports, potentially leading to tariffs or quotas within 180 days.
This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →